We are intrigued by the observation that the loss of TET2 function, which would be predicted to increase gene methylation, results in similar endpoints (development of inflammation and PAH) as those that occur with loss-of-function mutations of DNMT3A, which might be expected to reduce gene methylation. This evidence concerns the gene TET2 and pulmonary arterial hypertension.